摘要
目的研究参附强心丸联合卡维地洛片治疗充血性心力衰竭的临床疗效。方法选取2017年12月-2018年12月空军军医大学附属唐都医院收治的108例充血性心力衰竭患者为研究对象,将所有充血性心力衰竭患者采用照抽签方式分为对照组和治疗组,每组各54例。对照组患者口服卡维地洛片,开始2天剂量为12.5 mg/次,1次/d,以后25 mg/次,1次/d;治疗组在对照组患者基础上口服参附强心丸,2袋/次,3次/d。两组患者持续治疗4周。观察两组的临床疗效,比较两组的心功能指标、脑钠肽(BNP)、内皮素-1(ET-1)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)水平。结果治疗后,对照组和治疗组的总有效率分别为88.33%、96.30%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者左心室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)均显著降低,心指数(CI)、左室射血分数(LVEF)均显著升高,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组患者心功能指标显著高于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者BNP和ET-1水平均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组患者BNP和ET-1水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者hs-CRP、IL-6、TNF-α水平均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组患者hs-CRP、IL-6、TNF-α水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。结论参附强心丸联合卡维地洛片治疗充血性心力衰竭具有较好的临床疗效,能改善患者心功能,降低血清炎性因子水平,安全性较高,具有一定的临床推广应用价值。
Objective To study the effect of Shenfu Qiangxin Pills combined with Carvedilol Tablets in treatment of congestive heart failure. Methods Patients(108 cases) with congestive heart failure in Tangdu Hospital Affiliated to Air Force military Medical University from December 2017 to December 2018 were randomly divided into control and treatment groups, and each group had 54 cases. Patients in the control group were po administered with Carvedilol Tablets, the first 2 d for 12.5 mg/time, once daily, after that for 25 mg/time, once daily. Patients in the treatment group were po administered with Shenfu Qiangxin Pills on the basis of the control group, 2 bags/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and cardiac function indexes, the levels of BNP, ET-1, IL-6, hs-CRP and TNF-α in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 88.33% and 96.30%, respectively, and there was difference between two groups(P < 0.05). After treatment, LVESD and LVEDD in two groups were significantly decreased, but CI and LVEF in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the cardiac function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of BNP and ET-1 in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the levels of BNP and ET-1 in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the levels of IL-6, hs-CRP and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the levels of IL-6, hs-CRP and TNF-αin the treatment group were
作者
王长鹰
封仁乾
杨沛
韩杨
廉诚
WANG Chang-ying;FENG Ren-qian;YANG Pei;HAN Yang;LIAN Cheng(Department of Cardiovascular Medicine,Tangdu Hospital Affiliated to Air Force military Medical University,Xi'an 710038,China;Basic Medical College of Air Force military Medical University,Xi'an 710038,China;Graduate School of Air Force Military Medical University,Xi5an 710038,China)
出处
《现代药物与临床》
CAS
2019年第11期3250-3254,共5页
Drugs & Clinic
